Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.59 |
| ▸ | HPGD | P15428 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 5/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL29521813 | 1.00 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL4179751 | 0.98 | KDM4E (0.58) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29723505 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL3960 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1661720 | 0.98 | KDM4E (0.61) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9879420 | 0.97 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29367714 | 0.97 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9878595 | 0.97 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL9879191 | 0.97 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL3467 | 0.97 | KDM4E (0.59) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11887 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028914-A | Combination therapy for autoimmune disorders | 拜奥海芬治疗学有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260115209-A1 | COMBINATION THERAPY INCLUDING COX-2 INHIBITOR FOR THE TREATMENT OF CANCER | UNIV CALIFORNIA (US) | 2026-04-30 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250255781-A1 | PROCESSES FOR PREPARATION OF 3-D PRINTED PHARMACEUTICAL PRODUCTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-08-14 | — | — | US | claimed |
| US-12296043-B2 | Liquisoft capsules | PATHEON SOFTGELS INC. (US) | 2025-05-13 | — | — | US | claimed |
| WO-2025081174-A1 | COMBINATION TREATMENT OF AUTOIMMUNE DISORDERS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-04-17 | — | — | WO | claimed |
| CN-119792640-A | Filler composition, preparation method and application thereof | 渼颜空间(河北)生物科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| WO-2025076059-A1 | ROCAGLATE DERIVATIVES AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-04-10 | — | — | WO | claimed |
| WO-2025066019-A1 | TOPICAL DELIVERY COMPOSITIONS COMPRISING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANDROS PHARMACEUTICALS CO., LTD. (CN) | 2025-04-03 | — | — | WO | claimed |
| EP-4529917-A1 | TOPICAL DELIVERY COMPOSITIONS COMPRISING NON-STEROIDAL ANTI-INLAMMATORY DRUGS | Andros Pharmaceuticals Co., Ltd. (TW) | 2025-04-02 | — | — | EP | claimed |
| WO-1996006640-A1 | BIOADHESIVE-WOUND HEALING COMPOSITION | WARNER-LAMBERT COMPANY (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1996003149-A1 | ANTIFUNGAL-WOUND HEALING COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | WARNER-LAMBERT COMPANY (US) | 1996-02-08 | — | — | WO | claimed |
| WO-1996000584-A1 | ANTI-INFLAMMATORY WOUND HEALING COMPOSITIONS AND METHODS FOR PREPARING AND USING SAME | WARNER-LAMBERT COMPANY (US) | 1996-01-11 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0642336-A1 | USE OF NSIAD IN THE TREATMENT OF DEMENTIA | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1995-03-15 | — | — | EP | claimed |
| WO-1993024115-A1 | ANTI-RHEUMATOID ARTHRITIC DRUGS IN THE TREATMENT OF DEMENTIA | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1993-12-09 | — | — | WO | claimed |
| US-5192753-A | Anti-rheumatoid arthritic drugs in the treatment of dementia | SUN HEALTH CORPORATION, INC. | 1993-03-09 | — | — | US | claimed |
| US-5164379-A | Reduction of gastric irritation caused by medicines | BRISTOL-MYERS COMPANY (US) | 1992-11-17 | — | — | US | claimed |
| EP-0249561-B1 | COMPOSITIONS USING LIPOSOME-ENCAPSULATED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | THE LIPOSOME COMPANY, INC. (US) | 1992-05-13 | — | — | EP | claimed |
| US-5043168-A | Nonhygroscopic, antiarthritis agent, analgesic | SIDMAK LABORATORIES, INC. (US) | 1991-08-27 | — | — | US | claimed |